Published
In this presentation from the Association for Molecular Pathology (AMP) 2024 Annual Meeting, hear how Dr. Stephen Murphy, Director of the Genome Analysis Core, Mayo Clinic, is exploring the potential of nanopore sequencing for rapid clinical testing in cancer predisposition genes.
- Category
- Oncology
Be the first to comment
Up Next
-
05:20
Next-Gen Sequencing Tumor Testing Remains Low in Prostate and Urothelial Cancer Cases
-
04:06
Advantages of comprehensive cancer whole exome sequencing
-
11:22
Peanuts are both an aphrodisiac and a potential cause of cancer!
-
19:20
#CVM #NYSE! Cel-Sci is making waves proving its potential to revolutionize cancer treatment! Wow!
-
Vías de Reparación del ADN, otra vía para desarrollar cáncer, no todo son genes supresores
-
09:18
Long-Term Complications of Prostate Cancer Treatment: PSA Testing
-
04:48
The future of cancer research unlocking its transformative potential. #physicsoftheuniverse
-
13:33
Chapter 1.5.The Psychology of Testing-1.5.1 Human Psychology & Testing - 1.5.2 Tester & Dev mindset
-
04:22
Addressing potential biases in AI models for skin cancer diagnosis
-
08:12
Genomics & epigenomics in multiple myeloma: key updates and potential clinical applications
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
